Price for Spark gene therapy too high, ICER says – BioPharma Dive
Philadelphia Business Journal |
Price for Spark gene therapy too high, ICER says
BioPharma Dive Spark Therapeutics Inc.’s newly approved gene therapy for a rare form of blindness is too expensive to be considered cost-effective, according to a new report from a research organization known for its critiques of industry pricing practices. Currently … Nonprofit agency says Spark’s gene therapy $425K price tag is too highPhiladelphia Business Journal ICER report critical of Spark Therapeutics’ pricing of LuxturnaThe Pharma Letter |
BioPharma-Reporter.com |
Product characterisation key to successful CAR T therapies, Autolus
BioPharma-Reporter.com And speaking at last month’s Cell Therapy Manufacturing & Gene Therapy Congress in Amsterdam, Jim Faulkner, SVP and head of manufacturing at UK-based CAR T-cell therapy developer Autolus, said it was imperative to reduce the costs to allow such … |